Medical illustration for Based on WHO | Is fever a common symptom of mesothelioma, and what does its presence typically indicate? - Persly Health Information
Persly Medical TeamPersly Medical Team
February 15, 20265 min read

Based on WHO | Is fever a common symptom of mesothelioma, and what does its presence typically indicate?

Key Takeaway:

Fever can occur in mesothelioma but is less common than respiratory symptoms. Its presence may reflect tumor-related systemic inflammation or infection especially during therapy so any fever ≥38°C while on treatment warrants urgent evaluation.

Mesothelioma and Fever: How Common Is It and What Does It Mean?

Fever can occur in mesothelioma, but it is not the most prominent symptom compared with chest pain, shortness of breath, cough, and weight loss. Still, many clinical summaries list fever and night sweats among recognized systemic (whole‑body) signs, especially in pleural mesothelioma. [1] [2] Fever during or after treatment also warrants prompt medical assessment because it may signal infection or treatment‑related complications. [3] [4]


How Often Does Fever Occur?

  • Pleural mesothelioma commonly presents with chest pain, dyspnea (shortness of breath), cough, fatigue, weight loss, and can include fever and sweating/night sweats as part of the symptom spectrum. [1] [2]
  • Case series and registry analyses have documented fever at presentation in a subset of patients. For example, historical cohorts reported fever as an initial symptom in about a tenth of pleural cases, highlighting that while not universal, fever is a recognized presentation. [5]

In short, fever is possible and clinically relevant, but not as frequent as respiratory symptoms; its presence should be interpreted in clinical context. [2]


What Does Fever Typically Indicate?

1) Tumor‑Related Inflammation (Paraneoplastic)

Mesothelioma is strongly linked to chronic inflammation triggered by asbestos exposure. Systemic inflammation markers, such as elevated C‑reactive protein (CRP) and neutrophil‑to‑lymphocyte ratio (NLR), correlate with symptom burden and survival. [6] [7] Laboratory and animal model data suggest tumor production of inflammatory cytokines (notably interleukin‑6, IL‑6) can drive fever, weight loss, and thrombocytosis as paraneoplastic features. [8] These cytokine‑mediated effects may precede visible tumor growth and contribute to systemic symptoms. [8]

Clinically, higher baseline CRP (≥1 mg/dL) has been associated with shorter overall survival and appears to influence which treatment strategies confer benefit, supporting the idea that fever can reflect a heightened inflammatory state and more aggressive disease biology. [9] Elevated NLR and related indices similarly predict poorer outcomes. [10] [6]

2) Infection (Especially During Chemotherapy)

For those receiving mesothelioma therapies (e.g., platinum plus pemetrexed, with or without bevacizumab), fever can signal infection or neutropenic sepsis, a medical emergency. Guidance advises urgent contact with the care team or emergency evaluation for temperature ≥38°C, chills/shivers/sweats, sore throat or cough, rapid heartbeat, or feeling unwell. [3] [11] [12] During treatment, lung complications and infections are uncommon but can be serious, and fever is one of the warning signs. [13] [4]

3) Fluid Collections and Disease Progression

Recurring pleural effusion (fluid around the lung) and abdominal involvement in peritoneal mesothelioma can be associated with systemic symptoms like fever, night sweats, anorexia, and fatigue due to ongoing inflammation. [14] [7] In peritoneal mesothelioma, fever has been reported among presenting symptoms in multicenter series. [15]


Clinical Implications and Next Steps

  • Assessment matters: When fever occurs, clinicians typically evaluate for infection (including blood counts and cultures), check inflammatory markers (CRP, NLR), and reassess disease status (imaging, fluid analysis) to differentiate paraneoplastic inflammation from treatable infection. [9] [6] [3]
  • Prognostic context: Elevated systemic inflammation (e.g., high CRP or NLR) is linked with worse prognosis in malignant pleural mesothelioma, making fever one possible sign of a broader inflammatory profile. [9] [6] [10]
  • During therapy: A fever ≥38°C during chemotherapy or targeted therapy should prompt immediate contact with the oncology team or emergency care, given the risk of neutropenia or serious lung complications. [3] [11] [13] [4] [12]

Practical Guidance for Individuals With Mesothelioma

  • If you experience fever (≥38°C), chills, sweats, or feel suddenly unwell, especially while on treatment, seek medical advice promptly to rule out infection and complications. [3] [11] [12]
  • Persistent or recurrent fever outside treatment may reflect paraneoplastic inflammation; discussing tests for CRP, NLR, and other markers with your team can help guide prognosis and care planning. [9] [6] [7]
  • Track associated symptoms like night sweats, weight loss, appetite changes, cough, or shortness of breath, as this information helps your clinician determine whether the fever is primarily inflammation‑driven or infection‑related. [1] [2] [14]

Summary Table: Fever in Mesothelioma

AspectWhat it may indicateKey references
Presence of fever among symptomsRecognized systemic symptom; less common than respiratory complaints but clinically meaningful[1] [2] [5]
Paraneoplastic inflammationIL‑6–driven systemic effects (fever, weight loss); higher CRP/NLR linked to worse outcomes[8] [9] [6] [7]
Infection during therapyPotential neutropenic sepsis or lung complications; urgent evaluation for ≥38°C and chills/sweats[3] [11] [13] [4] [12]
Association with fluid collections/progressionEffusions and peritoneal involvement can accompany fever and systemic symptoms[14] [15]

Bottom Line

Fever is a known but variably present symptom in mesothelioma and can reflect either tumor‑related systemic inflammation or intercurrent infection, especially during treatment. [1] [2] Recognizing the context baseline inflammatory markers, treatment status, and accompanying symptoms helps clinicians determine urgency and tailor management. Any fever ≥38°C in someone receiving mesothelioma therapy should be treated as urgent until infection is ruled out. [3] [11] [12]

Related Questions

Related Articles

Sources

  1. 1.^abcdeMesotelioma maligno: MedlinePlus enciclopedia médica(medlineplus.gov)
  2. 2.^abcdefMesothelioma(medlineplus.gov)
  3. 3.^abcdefgPatient information - Mesothelioma - Cisplatin, pemetrexed and bevacizumab(eviq.org.au)
  4. 4.^abcdPatient information - Mesothelioma - Carboplatin, pemetrexed and bevacizumab(eviq.org.au)
  5. 5.^ab[An analysis of 310 cases of pleural mesothelioma].(pubmed.ncbi.nlm.nih.gov)
  6. 6.^abcdefInflammation-based prognostic indices in malignant pleural mesothelioma.(pubmed.ncbi.nlm.nih.gov)
  7. 7.^abcdHealth-related quality of life and inflammatory markers in malignant pleural mesothelioma.(pubmed.ncbi.nlm.nih.gov)
  8. 8.^abcInterleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.(pubmed.ncbi.nlm.nih.gov)
  9. 9.^abcdePretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis.(pubmed.ncbi.nlm.nih.gov)
  10. 10.^abThe value of inflammatory parameters in the prognosis of malignant mesothelioma.(pubmed.ncbi.nlm.nih.gov)
  11. 11.^abcdePatient information - Mesothelioma - Carboplatin, pemetrexed and bevacizumab(eviq.org.au)
  12. 12.^abcdePatient information - Mesothelioma - Carboplatin and pemetrexed(eviq.org.au)
  13. 13.^abcPatient information - Mesothelioma - Cisplatin, pemetrexed and bevacizumab(eviq.org.au)
  14. 14.^abcSymptoms of Peritoneal & Pleural Mesothelioma Cancers(mskcc.org)
  15. 15.^abMalignant peritoneal mesothelioma: a multicenter study on 81 cases.(pubmed.ncbi.nlm.nih.gov)

Important Notice: This information is provided for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any medical decisions.